Procalcitonin Level and the High Risk of Mortality in 30 Days in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patient , Cases Series.

Mohammed VI University Hospital

Status: Completed

Conditions: the Relationship Between Procalcitonin and 30-day Mortality in COVID Patients

Study type: Observational

Funder types: Other

Identifiers

NCT05008016

Anaesthesia and Resuscitation

Details and patient eligibility

About

Background:

Procalcitonin (PCT) is a biomarker that has been proposed as a helpful tool in inflammatory Clinique cases specially patient with pulmonary bacterienne infection .

Materials and methods the investigatore had retrospectively reviewed the electronic records and lists of all 582 COVID-19 patients admitted on the ICU of Hospital university Mohammed VI , Oujda. Between 01 juin 2020 and 31juanary 2021 , and analyzed the relation of PCT value and mortality at 30 days until we can defined a cut off Procalcitonine to use as a marker of severity and high mortality .

Full description

Our objective is to assess the relationship between Procalcitonin and 30-day mortality in patients admitted to the resuscitation department of the Mohammed VI University Hospital Center, Oujda, Morocco, infected by the SARS COV 2 Virus .

Enrollment: 582 patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of SARS COV2 infection needed admission in ICU .

Exclusion criteria

• patient under 15 ans

Trial design

582 participants in 1 patient group

Procalcitonine analysed

Description:

The invistagatore had analysed the Procalcitonine of patient that survived and the non Survived frome COVID infection in Intensive care departement